We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

How Genistein Slows Metastasis in Prostate Cancer

By LabMedica International staff writers
Posted on 12 Aug 2009
Cancer researchers have shown how the antiprostate cancer isoflavone genistein functions at the molecular level to inhibit expression of genes that favor metastasis and spread of the disease.

Investigators from Northwestern University (Chicago, IL, USA) were particularly interested in the relationship between dietary genistein and the expression of the MEK4 (mitogen-activated protein kinase 4) gene. Toward this end, they worked with cultures of six different prostate cancer-cell lines. All the cell lines were transiently transfected with a MEK4 gene (to increase MEK4 expression), small interfering RNA against MEK4 (to decrease MEK4 expression), or corresponding control materials. Gene expression was assessed by a quantitative reverse transcription–polymerase chain reaction, and protein expression was determined by Western blot analysis. Cell invasion was assessed by a Boyden chamber assay.

Results published in the July 28, 2009, online edition of the Journal of the National Cancer Institute revealed that overexpression of MEK4 increased the expression of the MMP-2 (matrix metalloproteinase-2) gene, which has been linked to cell invasion. Decreased MEK4 expression had the opposite effects. Computer modeling indicated that genistein bound to the active site of MEK4, while an enzymatic assay showed that genistein inhibited MEK4 kinase activity. The expression of MMP-2 was significantly higher in normal prostate epithelial cells taken from untreated prostate cancer patients than they were in cells taken from genistein-treated patients.

Summarizing the results of the study, the authors said, "We have shown that it is possible to target motility-associated processes with genistein in patients with prostate cancer; have identified MEK4 as the therapeutic target for genistein in all six prostate cell lines examined; and have provided a possible mechanism to link high dietary consumption of genistein-containing foods with lower rates of prostate cancer metastasis and mortality.”

Related Links:

Northwestern University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10

Latest BioResearch News

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
12 Aug 2009  |   BioResearch

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
12 Aug 2009  |   BioResearch

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
12 Aug 2009  |   BioResearch